Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 19/20 | 0.69 |
| ▸ | BRD4 | O60885 | 11/20 | 0.69 |
| ▸ | PLK3 | Q9H4B4 | 7/20 | 0.58 |
| ▸ | PLK2 | Q9NYY3 | 5/20 | 0.58 |
| ▸ | BRDT | Q58F21 | 4/20 | 0.58 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.58 |
| ▸ | PDXK | O00764 | 2/20 | 0.58 |
| ▸ | NEK3 | P51956 | 2/20 | 0.58 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.58 |
| ▸ | WEE1 | P30291 | 1/20 | 0.58 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.54 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.53 |
| ▸ | CLK2 | P49760 | 3/20 | 0.53 |
| ▸ | CAMK2G | Q13555 | 3/20 | 0.53 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.53 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.53 |
| ▸ | CSNK1G1 | Q9HCP0 | 3/20 | 0.53 |
| ▸ | CSNK1G3 | Q9Y6M4 | 3/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.53 |
| ▸ | PRKCG | P05129 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3644074 | 0.88 | PLK1 (0.74) | PLK1BRD4PLK3PLK2BRDT | |
| SCHEMBL31467393 | 0.88 | PLK1 (0.74) | PLK1BRD4PLK3PLK2BRDT | |
| SCHEMBL28344864 | 0.87 | PLK1 (0.78) | PLK1BRD4PLK3PLK2BRDT | |
| SCHEMBL12323787 | 0.87 | PLK1 (0.78) | PLK1BRD4PLK3PLK2BRDT | |
| SCHEMBL12323788 | 0.87 | PLK1 (0.75) | PLK1BRD4PLK3PLK2BRDT | |
| SCHEMBL12324588 | 0.87 | PLK1 (0.75) | PLK1BRD4PLK3PLK2BRDT | |
| SCHEMBL24782957 | 0.85 | PLK1 (0.78) | PLK1BRD4PLK3PLK2BRDT | |
| SCHEMBL13104992 | 0.83 | PLK1 (0.76) | PLK1BRD4PLK3PLK2BRDT | |
| SCHEMBL24782954 | 0.82 | PLK1 (0.78) | PLK1BRD4PLK3PLK2BRDT | |
| SCHEMBL4801607 | 0.82 | PLK1 (0.60) | PLK1BRD4PLK3PLK2BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786819-B1 | DIHYDROPTERIDINONE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2011-01-26 | — | — | EP | disclosed |
| US-7807831-B2 | Dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-05 | — | — | US | disclosed |
| US-7807831-B2 | Dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-05 | — | — | US | disclosed |
| US-7723517-B2 | Dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2010-05-25 | — | — | US | disclosed |
| US-7723517-B2 | Dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2010-05-25 | — | — | US | disclosed |
| US-7700769-B2 | Dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-20 | — | — | US | disclosed |
| US-7700769-B2 | Dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-20 | — | — | US | disclosed |
| US-7629460-B2 | Dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-08 | — | — | US | disclosed |
| US-7629460-B2 | Dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-08 | — | — | US | disclosed |
| US-7547780-B2 | Cyclin-dependent and serine/threonine kinases inhibitor; cell cycle arrest in the G2/M phase; antiproliferative and antitumor agent; leukemia, sarcoma, lung, breast, prostate, pancreas cancer; autoimmune diseases, arthritis, Alzheimer's disease | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-16 | — | — | US | disclosed |
| US-7414053-B2 | Dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-19 | — | — | US | disclosed |
| US-7414053-B2 | Dihydropteridione derivatives, process for their manufacture and their use as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-19 | — | — | US | disclosed |
| US-20080194818-A1 | Antiproliferative agents; polo-like kinase inhibitors | GRAUERT MATTHIAS | 2008-08-14 | — | — | US | disclosed |
| US-20080194818-A1 | Antiproliferative agents; polo-like kinase inhibitors | GRAUERT MATTHIAS | 2008-08-14 | — | — | US | disclosed |
| US-20080113992-A1 | Dihydropteridione Intermediate Compounds | GRAUERT MATTHIAS | 2008-05-15 | — | — | US | disclosed |
| US-20080113992-A1 | Dihydropteridione Intermediate Compounds | GRAUERT MATTHIAS | 2008-05-15 | — | — | US | disclosed |
| US-20080108812-A1 | Dihydropteridione Intermediate Compounds | GRAUERT MATTHIAS | 2008-05-08 | — | — | US | disclosed |
| US-20080108812-A1 | Dihydropteridione Intermediate Compounds | GRAUERT MATTHIAS | 2008-05-08 | — | — | US | disclosed |
| US-7332491-B2 | cyclin-dependent and serine/threonine kinases inhibitor; cell cycle arrest in the G2/M phase; antiproliferative and antitumor agent: leukemia, sarcoma, lung, breast, prostate, pancreas cancer; autoimmune diseases: arthritis, Alzheimer's disease | BOEHRINGER INGELHEIM INTERNATIONAL, GMBH (DE) | 2008-02-19 | — | — | US | disclosed |
| US-7332491-B2 | cyclin-dependent and serine/threonine kinases inhibitor; cell cycle arrest in the G2/M phase; antiproliferative and antitumor agent: leukemia, sarcoma, lung, breast, prostate, pancreas cancer; autoimmune diseases: arthritis, Alzheimer's disease | BOEHRINGER INGELHEIM INTERNATIONAL, GMBH (DE) | 2008-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113992-A1 | Dihydropteridione Intermediate Compounds | QDPR, DHPS, DHODH | PLK1 4155/4885BRD4 4385/4885PLK3 2335/4885 |
| US-20080194818-A1 | Antiproliferative agents; polo-like kinase inhibitors | CCNK, CDK1, PLK1 | PLK1 3/4885BRD4 2309/4885PLK3 72/4885 |
| US-20080108812-A1 | Dihydropteridione Intermediate Compounds | QDPR, DHPS, DHODH | PLK1 4155/4885BRD4 4385/4885PLK3 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.